Resumption of Anticoagulation After Gastrointestinal Bleeding in Atrial Fibrillation: A Scoping Review of Timing Strategies and Clinical Outcomes
Document Type
Conference Proceeding
Publication Date
11-2-2026
Publication Title
Circulation
Abstract
Background: Gastrointestinal bleeding (GIB) remains one of the most clinically important complications of oral anticoagulation in patients with atrial fibrillation (AF). Following hemostasis, clinicians must balance the competing risks of recurrent bleeding, thromboembolism, and death when determining whether and when anticoagulation should be resumed. We conducted a scoping review to map the available evidence regarding anticoagulation resumption after GIB in AF. Methods: This scoping review was performed according to the Arksey-O'Malley framework, subsequent methodological refinements, and PRISMA-ScR reporting standards. Embase, Web of Science, and MEDLINE records were screened after de-duplication. Two independent reviewers performed study selection and data charting. Evidence was synthesized across three clinically relevant domains: restart versus non-restart, early versus delayed restart, and direct oral anticoagulant (DOAC) versus warfarin restart strategies. Results: A total of 1,632 records were identified, with 897 unique records remaining after de-duplication. Nine primary studies met eligibility criteria and were included in the final evidence map. Across the literature, resumption of anticoagulation was generally associated with lower thromboembolic risk and lower mortality compared with permanent discontinuation. Several cohorts suggested that restarting anticoagulation within 7 days after hemostasis may be feasible in selected patients without a substantial increase in recurrent GIB, while prolonged interruption was consistently associated with greater thromboembolic concern. More recent comparative studies favored DOAC-based resumption over warfarin, demonstrating lower recurrent bleeding while maintaining thromboembolic protection. Conclusions: Among patients with AF who experience GIB, resumption of anticoagulation after hemostasis appears preferable to indefinite discontinuation in most cases. Timing should be individualized, but the most consistent themes across the literature were avoidance of prolonged interruption, early reassessment after hemostasis, and preference for DOAC-based resumption when clinically appropriate.
Volume
154
Issue
Suppl 1
Recommended Citation
Eltayeb M, Ahmed M, Salih MS, Elhussain M, Towfig MF, Mohamedshata A, et al. [Ahmed MEAM, Abu Daya H]. Resumption of anticoagulation after gastrointestinal bleeding in atrial fibrillation: a scoping review of timing strategies and clinical outcomes. Circulation. 2026 Nov 2;154(Suppl 1). doi:10.1161/circ.154.suppl_1.10090
DOI
10.1161/circ.154.suppl_1.10090
Comments
American Heart Association Scientific Sessions and the American Heart Association Resuscitation Science Symposium, November 6-9, 2026, Chicago, IL